Recommendation of final dividend, subject to the approval of the shareholders at the ensuing Annual General Meeting.
AARTIPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.8 pts less than Nifty Microcap 250 and 5.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Aarti Pharmalabs board has recommended a final dividend of Rs. 2 per equity share (40% payout) for FY ended March 2026, pending shareholder approval at the AGM. Standalone revenue grew marginally to Rs. 1,79,755 lakhs from Rs. 1,77,135 lakhs, but net profit dropped significantly to Rs. 17,620 lakhs from Rs. 25,735 lakhs in FY25 - a decline of about 31.5%. EPS for the year stood at Rs. 19.44 compared to Rs. 28.39 in the previous year. The company also recognized Rs. 279.49 lakhs as exceptional item for new labour code provisions and Rs. 2,972.94 lakhs fair value loss on a forex derivative contract. Cost auditor and internal auditor were re-appointed, and two senior management personnel were designated.
The company maintained the same Rs. 2 dividend despite a 31.5% profit decline, which may signal management confidence but also raises questions about dividend sustainability. The sharp drop in profitability could weigh on the stock price in the near term.